Navigation Links
Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
Date:3/24/2010

Monthly dialogues replace annual reviews to give employees more ‘real time’ feedback. Employee development is a priority at Merrimack, which has hired 50 people since October 2009 and is a recipient of a $1.5 million Massachusetts Life Sciences Center tax incentive award for job creation.

Cambridge, Mass (PRWEB) March 24, 2010 -- Merrimack Pharmaceuticals was one of 18 winners out of more than 100 entries in Human Resources magazine’s second annual competition for the most noteworthy HR ideas. Awards were in four categories: Benefits, HR Technology, Talent Management and Training & Development.

Merrimack was recognized in the Talent Management category for the company’s decision last year to replace its semi-annual review process with 12 monthly employee dialogue sessions. “Talking monthly helps ensure that managers are actively involved in their employees’ development and creates alignment around team and company objectives,”    said Andy Porter, senior director of Human Resources, at Merrimack. “As Merrimack continues to grow, it’s critically important that we have a strong foundation of manager-employee feedback in place.” The dialogues include: goal check-in, job competencies and development, one actionable item the employee can improve, and types of support the manager can provide.

About Merrimack
Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

###

Read the full story at http://www.prweb.com/releases/merrimackpharma/hraward/prweb3770804.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
2. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
3. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
7. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
11. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
(Date:1/24/2017)... (PRWEB) , ... January 24, ... ... the release of Version 5.0 of its award-winning CERF ELN ... a 21CFR11 compliant, collaborative, knowledge asset manager used by laboratories, regulated scientific ...
(Date:1/24/2017)... SANTA CLARA, Calif. , Jan. 24, 2017  Frost & ... chairman of the Fonar Corporation, will receive special recognition at the ... , taking place March 19 to 21, 2017 at the Loews ... To register and download the event agenda for ... www.frost.com/medtech ...
(Date:1/24/2017)... , Jan. 24, 2017   Bracket , a ... announced the addition of Jennifer Peters to ... President and General Manager for the Scientific Services division. ... Bracket,s work in Rater Training, Quality Assurance, and Electronic ... a strong skillset and demonstrated record building technology-based businesses ...
(Date:1/24/2017)... MONTREAL , Jan. 24, 2017 /PRNewswire/ - BioAmber Inc. ... demand, the underwriters have agreed to increase the size of ... stock of the Company, together with warrants to purchase 1,842,106 ... price of US$5.50 per share of common stock (the "Exercise ... share and associated warrant (the "Public Price"). The warrants have ...
Breaking Biology Technology:
(Date:1/19/2017)... India , January 19, 2017 According to a ... Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is expected ... 2016 to 2022. In 2015, Asia-Pacific dominated the global ... and private sectors. Continue Reading ... ...
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/11/2017)... Iowa , Jan. 11, 2017 Intoxalock, ... first with the release of its patent-pending calibration device. ... and reliably perform calibrations, securely upload data logs and ... for the customer. "Fighting drunk driving through ... for the public at large, but also for the ...
Breaking Biology News(10 mins):